listeo-data-scraper domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/healingmaps.imarkdev.com/wp-includes/functions.php on line 6170
Definium's DT120 met its primary endpoint in the Panorama trial. A low-dose arm was added to address functional unblinding, and a dose-response pattern emerged.
Read More
Virginia passed a trigger law for FDA-approved psilocybin, and both Compass Pathways and Journey Clinical plan to launch at existing Spravato sites.
Read More
FDA heard four hours of testimony on psychedelic approval and asked no questions. The real contest was over label language, which decides who can deliver these drugs.
Read More
A Center for Health Care Strategies report examines how psychedelic-assisted therapy could reach Medicaid. Some states already cover off-label IV ketamine.
Read More
Johnson & Johnson, Mindbloom and BetterU are all bidding on generic psychedelic search terms. Here is what that does to a local clinic's acquisition cost.
Read More
A Science paper found psilocybin prevented chemotherapy nerve damage in mice across six treatment cycles. A non-hallucinogenic compound did the same.
Read More
The WSJ reported that a SpaceX director gave $25 million to recapitalize the company behind MDMA-assisted therapy. That explains a strategy that looked strange.
Read More
The American Legion adopted a resolution backing psychedelic therapy for veterans. It endorses S.4220, which would build a VA office and ban step therapy.
Read More
Bipolar patients are routinely screened out of ketamine treatment over mania risk. A midazolam-controlled trial in JAMA Psychiatry finally tested the question.
Read More
FDA cited Alar Pharmaceuticals over claims for an investigational ketamine product. The flagged phrases show up in a lot of clinic marketing.
Read More